Myriad Genetics (MYGN) Expected to Announce Earnings on Tuesday

Myriad Genetics (NASDAQ:MYGN) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $200.37 million for the quarter.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The company had revenue of $210.60 million during the quarter, compared to analyst estimates of $210.35 million. During the same quarter in the previous year, the business posted ($0.12) EPS. On average, analysts expect Myriad Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Myriad Genetics Stock Performance

Myriad Genetics stock opened at $7.36 on Tuesday. Myriad Genetics has a 12-month low of $7.16 and a 12-month high of $29.30. The stock has a market capitalization of $678.47 million, a price-to-earnings ratio of -5.66 and a beta of 1.87. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The stock has a 50-day simple moving average of $9.40 and a 200 day simple moving average of $13.50.

Analyst Ratings Changes

A number of research firms have recently commented on MYGN. Piper Sandler raised Myriad Genetics from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $11.50 to $12.50 in a report on Wednesday, March 12th. Bank of America decreased their price objective on Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating for the company in a report on Monday, March 3rd. StockNews.com raised Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Thursday, April 10th. Stephens reiterated an “equal weight” rating and issued a $20.00 price target on shares of Myriad Genetics in a research report on Thursday, January 16th. Finally, The Goldman Sachs Group decreased their price objective on shares of Myriad Genetics from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, April 17th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Myriad Genetics currently has a consensus rating of “Hold” and a consensus target price of $20.61.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.